BMRN Biomarin Pharmaceutical
- 84.620
- +1.290+1.55%
Biomarin Pharmaceutical News
Biomarin Pharmaceutical | 144: Notice of proposed sale of securities pursuant to Rule 144
Biomarin Pharmaceutical | 10-Q: Quarterly report
Biomarin Pharmaceutical | 8-K: BioMarin Reports Record Financial Results for the First Quarter 2024
Biomarin Pharmaceutical | 8-K: Current report
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Director BIENAIME JEAN JACQUES
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Burkhart Erin
Biomarin Pharmaceutical | 144: Notice of proposed sale of securities pursuant to Rule 144
Biomarin Pharmaceutical | 144: Notice of proposed sale of securities pursuant to Rule 144
Biomarin Pharmaceutical | 144: Notice of proposed sale of securities pursuant to Rule 144
Biomarin Pharmaceutical | DEF 14A: Definitive information statements
Biomarin Pharmaceutical | ARS: Annual Report to Security Holders
Biomarin Pharmaceutical | DEFA14A: Others
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Davis George Eric
Biomarin Pharmaceutical | 144: Notice of proposed sale of securities pursuant to Rule 144
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Director Slamon Dennis
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Burkhart Erin
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Davis George Eric
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Guyer Charles Greg
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer Mueller Brian
Biomarin Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Officer FUCHS HENRY J
Analysis
Price Target
No Data
